SmallMolecule Anti-infective Drug Market, by Product Type (Antibiotics (BLactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides,and Others), Antifungal ( Azoles, Echinocandins, Polyenes, and Others),Antivirals (Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside ReverseTranscriptase Inhibitors, and Others), and Others (Anthelminthic andAntiprotozoal), by Indication (Pneumonia, MRSA Infections, MSSA Infections,Sinusitis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis,Hepatitis, HIV Infection, Respiratory Tract Infection, Urinary Tract Infection,and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies,and Online Pharmacies), and by Region (North America, Europe, Asia Pacific,Latin America, Middle East, and Africa) - Global Industry Insights, Trends,Outlook, and Opportunity Analysis, 2019 – 2026
Small molecule anti-infectivedrugs are used for the treatment of various infectious diseases such asMethicillin-resistant Staphylococcus aureus (MRSA) infections,Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis,cellulitis, pneumonia, tuberculosis, aspergilosis, and hepatitis.Anti-infective drugs have the capability to eliminate and suppress infectionsthat are caused by various bacteria and viruses.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2655
Small Molecule Anti-infectiveDrug Market Drivers
Increasing approval of new drugsis expected to drive growth of the global small molecule anti-infective drugmarket. For instance, in April 2019, the U.S. Food and Drug Administration(FDA) announced the approval of Dovato (dolutegravir and lamivudine), which isused for the treatment of HIV-1 infection in adults. It is manufactured by ViiVHealthcare.
Furthermore, in August 2018,Tetraphase Pharmaceuticals received the U.S. Food and Drug Administrationapproval for its new drug, Xerava containing Eravacycline, which is used forthe treatment of complicated intra-abdominal infections (CIAI).
Small Molecule Anti-infectiveDrug Market Restraints
Increasing severe side effect ofdrugs is the major restraining factor of anti-infective drug market, it isexpected to the hamper the small molecule anti-infective drug market growth.For instance, NBC news report in December 2018, U.S Food and drugadministration sends warning letters to Fluroquinonolone antibiotics becauseU.S FDA found that Fluroquinolones antibiotic can increase the occurrence of seriousevents of rupture in the main artery of the body. These ruptures called as theaortic dissections.
Small Molecule Anti-infectiveDrug Market Regional Analysis
On the basis of region, theglobal small molecule anti-infective drug market is segmented into NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/small-molecule-anti-infective-drug-market-2655
North America is expected to holddominant position in the small molecule anti-infective drugs market, owing tonew product launches of small molecule anti-infective drugs. For instance, inNovember 2018, Xellia Pharmaceuticals launched its new product, VancomycineHydrochloride for injection, in the U.S market.
Furthermore, Asia Pacific is alsoprojected to witness significant growth in the global small moleculeanti-infective drugs market, owing to increasing collaboration activities amongkey players. For instance, in April 2018, Entasis Therapeutics Holdings Inc.collaborated with the Zai Lab Limited. This collaboration facilitated phase IIIclinical trial for a fixed-dose combination of ETX2514 and sulbactam. Thiscombination is intended for the treatment of multidrug-resistant infectionscaused by Acinetobacter baumannii bacteria. The study started in April 2019 andis expected to complete in July 2020.
Key players operating in theglobal small molecule anti-infective market include, Merck & Co., Inc.,AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG,Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2655
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
